A — Agilent Technologies, Inc.
Is A overbought or oversold? Here is the current MarketMoodz read.
Agilent Technologies, Inc. (A) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $172.22. The rating moved from Oversold to Neutral on November 17, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$172.22
- Last changeMoved from Oversold to Neutral on November 17, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
AI analysis
Agilent Technologies, Inc. (A) benefits from a diversified mix of instruments, consumables and services that generate recurring revenue and relatively steady cash flow. Healthy exposure to biopharma R&D and specialty drug growth supports medium-term instrument and consumable demand, while a solid market position and product portfolio provide competitive advantages. Near-term upside is supported by stable market sentiment toward healthcare and selective growth catalysts, though macro-sensitive capital spending, competitive pressures and execution/supply risks warrant monitoring.
Key factors
- Diversified exposure to life sciences, diagnostics and biopharma services supporting steady instrument and consumable demand
- Recurring revenue mix (consumables, services, software) that supports margin resiliency and cash flow generation
- Benefit from secular growth in biopharma R&D, specialty pharmaceuticals and increased chronic therapy monitoring that drive lab and testing volumes
- Strong market position in analytical instruments and lab services with high switching costs for customers
- Balance-sheet flexibility to invest in R&D, tuck-in M&A and share repurchases which can support long-term EPS
- Defensive flows into healthcare and large-cap pharma strength that can indirectly support demand through distributor and specialty channels
Risks
- Cyclical capital spending at academic and industrial labs could slow in a macro downturn, reducing instrument orders
- Intense competition and pricing pressure in certain instrument categories could compress margins over time
- Supply-chain disruptions or component shortages that delay deliveries and revenue recognition
- Foreign-exchange volatility given global revenue footprint
- Regulatory or reimbursement changes in end markets that could alter testing volumes or customer purchasing patterns
- Execution risk on integrating acquisitions or scaling new products into higher-margin recurring revenue
See today's live rating, score and targets
Members see the live hourly rating for A — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.